This peer-to-peer discussion reviews the current strategies for managing patients with melanoma, including screening and prognosis for high-risk patients and how to choose the best therapies to avoid toxicities and treatment resistance.
Ahmad A. Tarhini, MD, PhD
The unprecedented advances in melanoma immunotherapy are sure to pave the way for immunotherapy development in other tumors.
While the last several decades saw a lack of progress in treatment outcomes in this setting, the outlook has recently changed dramatically, driven by a deepening understanding of melanoma biology and host immunology.
Each year, nearly 60,000 new cases of melanoma are reported in the United States. The vast majority of these are cured by surgery. However, 8,000 of these patients are found to have metastatic melanoma beyond the scope of surgical cure—and this number closely approximates the annual number of deaths from this disease. This statistic illustrates the lack of progress that had been made in the treatment of advanced melanoma over the last several decades.
Annually, about 8,000 patients are found to have metastatic melanoma presenting as recurrence of an earlier primary melanoma, and this number closely approximates the annual number of deaths from the disease. This statistic illustrates the lack of progress that has been made in the treatment of stage IV melanoma over the past several decades.